Osaka Chemists Crack a Longstanding Problem in Making Drug Molecules

Two molecules can share an identical chemical formula and the same sequence of bonds yet behave completely differently inside a living cell. This is the reality of diastereomers - molecules that are structurally identical but arranged differently in three-dimensional space. Unlike mirror-image pairs, diastereomers are not reflections of each other; they are distinct geometric configurations that can have entirely different biological activities, toxicities, and potencies.

For pharmaceutical chemists, making the right diastereomer is not a preference - it is often a prerequisite for a drug to work. Yet organic synthesis has long been biased. When chemists run standard reactions on certain key building blocks, one diastereomeric form dominates the product mixture, and the other remains frustratingly scarce. A team at the University of Osaka has now described a strategy that inverts this outcome.

What Makes the Anti-Form So Hard to Make

The problem centers on a class of molecular building blocks called alpha-oxy carbonyl compounds. These are common intermediates in the synthesis of pharmaceuticals and natural products. A carbon atom adjacent to a carbonyl group sits next to an oxygen-containing substituent, creating a structural motif that shows up repeatedly in biologically active molecules.

When a nucleophile - a species that donates electrons - attacks the carbonyl group of one of these compounds, it can approach from two faces. The attack that occurs opposite to the existing oxygen substituent produces what chemists call the syn-adduct. The attack on the same face as the oxygen produces the anti-adduct. Standard chemistry strongly favors the syn outcome because the oxygen group coordinates with metal atoms in the reaction, steering incoming nucleophiles to the same side - a phenomenon called chelation control.

The result is that the anti-diastereomer, which may be the pharmacologically active form for a given drug target, ends up as a minor byproduct rather than the main product. Getting it in useful quantities has required complex, multi-step workarounds.

A Cage Structure That Blocks Chelation

Lead author Yuya Tsutsui and senior author Makoto Yasuda identified a structural fix: use an allylating agent whose geometry physically prevents chelation from operating. They chose a class of compounds called allylatranes - allyl groups built around a central atom (from Group 14 of the periodic table, such as carbon or silicon) that is bonded to a large number of surrounding atoms in a rigid, cage-like framework.

"We selected an allyl with a cage-like structure, an allylatrane. In this molecule, a large number of atoms are bonded to a central atom from Group 14," Tsutsui explained. "This high coordination number makes the allylatrane highly nucleophilic."

The rigid cage structure does something crucial: it makes the allylatrane far less reactive toward Lewis acids - the electron-accepting species that typically facilitate chelation. With chelation blocked, the reaction no longer defaults to producing the syn-adduct. Instead, the steric geometry of the encounter favors the anti-diastereomer as the primary product.

"Our strategy is applicable to a wide variety of substrates," Yasuda said. "The anti-diastereomer can be obtained in considerably higher yields than those afforded by traditional methods."

The paper, titled "Non-Chelation Control in Allylations of alpha-Oxy Ketones Using Group-14 Allylatranes," was published in Nature Communications with DOI: https://doi.org/10.1038/s41467-026-69732-2.

Practical Scope and Limitations

The team tested the approach across multiple substrate types and found the anti-selectivity held across a range of alpha-oxy carbonyl compounds - not just for a single optimized example. This breadth matters for practical pharmaceutical synthesis, where chemists need a reliable method that works across a series of structurally related compounds rather than one that must be re-optimized for each new target.

The study is conducted at the laboratory scale and the yields, while significantly improved over traditional methods, have not yet been demonstrated in industrial-scale synthesis runs. Whether the allylatrane reagents are easy and inexpensive to produce in large quantities remains a practical question that manufacturing teams would need to address before the approach could be adopted broadly in drug production.

For now, the value is in proof of concept: a simple, direct route to a molecular form that previously required complex synthetic gymnastics. For researchers building complex drug-like structures from modular components, having reliable access to both diastereomeric forms of a key building block doubles the chemical space they can explore.